1. Participants must have histologically or cytologically confirmed diagnosis of one of
the following differentiated thyroid cancer (DTC) subtypes:
1. Papillary thyroid cancer (PTC)
- • Follicular variant
- • Variants (including but not limited to tall cell, columnar cell,
cribriform-morular, solid, oxyphil, Warthin's-like, trabecular, tumor with
nodular fasciitis-like stroma, Hürthle cell variant of papillary carcinoma,
2. Follicular thyroid cancer (FTC)
- • Hurthle cell
- • Clear cell
- • Insular
2. Measurable disease meeting the following criteria and confirmed by central
1. At least 1 lesion of ≥1.0 cm in the longest diameter for a non-lymph node or ≥1.5
cm in the short-axis diameter for a lymph node that is serially measurable
according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) using
computed tomography/magnetic resonance imaging (CT/MRI). If there is only 1
target lesion and it is a non-lymph node, it should have a longest diameter of
2. Lesions that have had external beam radiotherapy (EBRT) or locoregional therapies
such as radiofrequency (RF) ablation must show evidence of progressive disease
based on RECIST 1.1 to be deemed a target lesion.
3. Participants must show evidence of disease progression within 12 months (an additional
month will be allowed to accommodate actual dates of performance of screening scans,
ie, within ≤13 months) prior to signing informed consent, according to RECIST 1.1
assessed and confirmed by central radiographic review of CT and/or MRI scans.
4. Participants must be Iodine-131 refractory/resistant as defined by at least one of the
1. One or more measurable lesions that do not demonstrate iodine uptake on any
2. One or more measurable lesions that have progressed according to RECIST 1.1
within 12 months (an additional month will be allowed to accommodate actual dates
of performance of screening scans, ie, within ≤13 months) after Iodine-131
therapy, despite demonstration of radioiodine avidity at the time of that
treatment by pre- or posttreatment scanning. These participants must not be
eligible for possible curative surgery.
3. Cumulative activity of Iodine-131 of >600 mCi or 22 gigabecquerels (GBq), with
the last dose administered at least 6 months prior to study entry.
5. Participants with known brain metastases who have completed whole brain radiotherapy,
stereotactic radiosurgery or complete surgical resection, will be eligible if they
have remained clinically stable, asymptomatic, and off steroids for one month.
6. Participants must be receiving thyroxine suppression therapy and thyroid stimulating
hormone (TSH) should not be elevated (TSH should be ≤5.50 mcIU/ML). When tolerated by
the participant, thyroxine dose should be changed to achieve TSH suppression (TSH
<0.50 mcIU/ML) and this dose may be changed concurrently upon starting study drug
7. All chemotherapy or radiation-related toxicities must have resolved to Grade <2
severity per Common Terminology Criteria for Adverse Events (CTCAE v4.03), except
alopecia and infertility.
8. Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status
of 0, 1, or 2.
9. Adequately controlled blood pressure (BP) with or without antihypertensive
medications, defined as BP ≤150/90 mmHg at Screening and no change in antihypertensive
medications within 1 week prior to Cycle 1/Day 1.
10. Adequate renal function defined as calculated creatinine clearance ≥30 mL/min per the
Cockcroft and Gault formula.
11. Adequate bone marrow function:
1. Absolute neutrophil count (ANC) ≥1500/mm3 (≥1.5 × 103/uL)
2. Platelets ≥100,000/mm3 (≥100 × 109/L)
3. Hemoglobin ≥9.0 g/dL
12. Adequate blood coagulation function as evidenced by an International Normalized Ratio
13. Adequate liver function:
1. Bilirubin ≤1.5 × upper limit of normal (ULN) except for unconjugated
hyperbilirubinemia or Gilbert's syndrome.
2. Alkaline phosphatase, alanine aminotransferase (ALT), and aspartate
aminotransferase (AST) ≤3 × ULN (≤5 × ULN if participant has liver metastases).
If alkaline phosphatase is >3 × ULN (in absence of liver metastases) or >5 × ULN
(in presence of liver metastases) AND the participant also is known to have bone
metastases, the liver-specific alkaline phosphatase must be separated from the
total and used to assess the liver function instead of total alkaline
14. Males or females age ≥18 years at the time of informed consent.
15. Females must not be lactating or pregnant at Screening or Baseline (as documented by a
negative beta-human chorionic gonadotropin [B-hCG] test with a minimum sensitivity of
25 IU/L or equivalent units of B-hCG. A separate baseline assessment is required if a
negative screening pregnancy test was obtained more than 72 hours before the first
dose of study drug.
16. All females will be considered to be of childbearing potential unless they are
postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age
group and without other known or suspected cause) or have been sterilized surgically
(ie, bilateral tubal ligation, total hysterectomy or bilateral oophorectomy, all with
surgery at least 1 month before dosing).
17. Females of childbearing potential should avoid becoming pregnant and use highly
effective contraception while on treatment with lenvatinib and for at least 1 month
after finishing treatment. Females of childbearing potential must not have had
unprotected sexual intercourse within 30 days before study entry and must agree to use
a highly effective method of contraception (eg, total abstinence, an intrauterine
device, a contraceptive implant, an oral contraceptive, or have a vasectomized partner
with confirmed azoospermia) throughout the entire study period and for 30 days after
study drug discontinuation. Females who are using hormonal contraceptives must have
been on a stable dose of the same hormonal contraceptive product for at least 4 weeks
before dosing and must continue to use the same contraceptive during the study and for
30 days after study drug discontinuation. Women using oral hormonal contraceptives
should add a barrier method.
18. Participants must voluntarily agree to provide written informed consent.
19. Participants must be willing and able to comply with all aspects of the protocol.
1. Anaplastic or medullary carcinoma of the thyroid.
2. Diagnosed with meningeal carcinomatosis.
3. Two or more prior vascular endothelial growth factor (VEGF)/vascular endothelial
growth factor receptor (VEGFR)-targeted therapies or any ongoing treatment for RR-DTC
other than TSH-suppressive thyroid hormone therapy.
4. Prior treatment with lenvatinib.
5. Participants who have received any anticancer treatment within 21 days or any
investigational agent within 30 days (or 5 half-lives) prior to the first dose of
study drug and should have recovered from any toxicity related to previous anticancer
treatment. This does not apply to the use of TSH suppressive thyroid hormone therapy.
6. Major surgery (eg, laparotomy, thoracotomy or joint replacement) within 3 weeks prior
to randomization or elective surgery scheduled to be performed during the study.
7. Participants having >1+ proteinuria on urine dipstick testing will undergo 24-hour
urine collection for quantitative assessment of proteinuria. Participants with urine
protein ≥1 g/24 h will be ineligible.
8. Gastrointestinal malabsorption or any other condition that in the opinion of the
investigator might affect the absorption of study drug.
9. Significant cardiovascular impairment: history of congestive heart failure greater
than New York Heart Association (NYHA) Class II, unstable angina, myocardial
infarction or cerebral vascular accident within 6 months of the first dose of study
drug, or cardiac arrhythmia associated with hemodynamic instability.
10. Prolongation of corrected QT interval (QTc) to >480 ms as demonstrated by a repeated
electrocardiogram (ECG) or a clinically significant ECG abnormality, including a
marked prolonged QT/QTc interval (eg, a repeated demonstration of a QTc interval >500
11. Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to
the first dose of study drug.
12. Active infection (any infection requiring treatment).
13. Active malignancy (except for DTC or definitively treated melanoma in-situ, basal or
squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix) within the
past 24 months.
14. Bleeding or thrombotic disorders.
15. Known intolerance to study drug (or any of the excipients).
16. Any medical or other condition that in the opinion of the investigator(s) would
preclude the participant's participation in a clinical study.
17. Females who are pregnant or breastfeeding.